IDO1 Antibody – 174Yb

Catalog: 717407                                        Clone: EPR20374                                         Isotype: Rabbit IgG
Reactivity: Human*
Storage: IDO1 antibody is supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

IHC: IDO1 staining of FFPE human tonsil
MIBI: IDO1 staining (cyan) of FFPE human tonsil, costained with dsDNA (magenta)

IHC: IDO-1 antibody staining of FFPE human lymphoma

MIBI: IDO-1 staining (cyan) of FFPE human lymphoma, counterstained with dsDNA (magenta)

Background: IDO1 (indolamine 2,3-dioxygenase) catalyzes the conversion of the essential amino acid tryptophan to N-formylkynurenine.  IDO1 is expressed by suppressive macrophages and in some tumor cells. IDO1 is induced by interferon gamma. The reduction of tryptophan in the tumor microenvironment and the production of kynurenine inhibit T cell responses and contribute to a suppressed immune state. Inhibition of IDO1 is an area of active research in cancer immunotherapy, particularly in combination with other therapies.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

Recommended Usage:Human FFPE: 3 ug/mL dilution. For optimal results, the antibody should be titrated for each desired application.

References

  • Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K.L,, Wu, M., Wainwright, D.A. IDO1 in cancer: a Gemini of immune checkpoints. Cellular & Molecular Immunology. 2018; 15:447–457.

* Conjugate tested on human tissue.

Contact Us

<p style="text-align: center; margin-top: 2em;">Let us know how we can help you.</p>


    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther

    255

    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing marketing@ionpath.com.

    X
    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.